Surmodics (NASDAQ:SRDX) Rating Reiterated by Sidoti

Surmodics (NASDAQ:SRDX – Get Free Report)‘s stock had its “neutral” rating reiterated by research analysts at Sidoti in a research note issued to investors on Wednesday, Benzinga reports. They presently have a $43.00 price objective on the stock. Sidoti’s price objective points to a potential upside of 2.09% from the company’s current price. Other equities […]

Related Keywords

Los Angeles ,California ,United States , ,Moody National Bank Trust Division ,Vanguard Group Inc ,Barrington Research ,Acadian Asset Management ,Surmodics Inc ,Sg Americas Securities ,Needham Company ,Los Angeles Capital Management ,Get Free Report ,Angeles Capital Management ,Asset Management ,National Bank Trust Division ,Medical Device ,Vitro Diagnostics ,Surmodics Daily ,